Search

Your search keyword '"Jenkins, Robert"' showing total 4,215 results

Search Constraints

Start Over You searched for: Author "Jenkins, Robert" Remove constraint Author: "Jenkins, Robert"
4,215 results on '"Jenkins, Robert"'

Search Results

201. Suppl. Table 1 from Approaching a Scientific Consensus on the Association between Allergies and Glioma Risk: A Report from the Glioma International Case-Control Study

202. Table S2 from Genomic and Phenotypic Characterization of a Broad Panel of Patient-Derived Xenografts Reflects the Diversity of Glioblastoma

203. Supplementary Figure Legend from Tumorgrafts as In Vivo Surrogates for Women with Ovarian Cancer

204. Supplemental Information from IGF1R Protein Expression Is Not Associated with Differential Benefit to Concurrent Trastuzumab in Early-Stage HER2+ Breast Cancer from the North Central Cancer Treatment Group (Alliance) Adjuvant Trastuzumab Trial N9831

205. Supplementary Table 7 from Transcriptome-Wide Association Study Identifies New Candidate Susceptibility Genes for Glioma

206. Supplementary Figures 1 - 3 from SSBP2 Variants Are Associated with Survival in Glioblastoma Patients

207. Supplementary Figure from Temozolomide and Radiotherapy versus Radiotherapy Alone in Patients with Glioblastoma, IDH-wildtype: Post Hoc Analysis of the EORTC Randomized Phase III CATNON Trial

208. Data from A Variable Age of Onset Segregation Model for Linkage Analysis, with Correction for Ascertainment, Applied to Glioma

209. Data from Sleeping Beauty Insertional Mutagenesis Reveals Important Genetic Drivers of Central Nervous System Embryonal Tumors

210. Supplementary Methods from A Variable Age of Onset Segregation Model for Linkage Analysis, with Correction for Ascertainment, Applied to Glioma

211. Supplementary Table 1 from A Variable Age of Onset Segregation Model for Linkage Analysis, with Correction for Ascertainment, Applied to Glioma

212. Supplementary Figure 4 from A Variable Age of Onset Segregation Model for Linkage Analysis, with Correction for Ascertainment, Applied to Glioma

213. Supplementary Figure 3 from A Variable Age of Onset Segregation Model for Linkage Analysis, with Correction for Ascertainment, Applied to Glioma

215. Supplementary data from MicroRNA-194 Promotes Prostate Cancer Metastasis by Inhibiting SOCS2

216. Supplementary Figures 1 - 4 from Tumorgrafts as In Vivo Surrogates for Women with Ovarian Cancer

217. Supplementary Table S2 from A Heritable Missense Polymorphism in CDKN2A Confers Strong Risk of Childhood Acute Lymphoblastic Leukemia and Is Preferentially Selected during Clonal Evolution

218. Data from Transcriptome-Wide Association Study Identifies New Candidate Susceptibility Genes for Glioma

219. Supplementary Table 6 from Transcriptome-Wide Association Study Identifies New Candidate Susceptibility Genes for Glioma

220. Supplementary Table 5 from Transcriptome-Wide Association Study Identifies New Candidate Susceptibility Genes for Glioma

221. Data from IGF1R Protein Expression Is Not Associated with Differential Benefit to Concurrent Trastuzumab in Early-Stage HER2+ Breast Cancer from the North Central Cancer Treatment Group (Alliance) Adjuvant Trastuzumab Trial N9831

222. Supplementary Figure 1 from A Variable Age of Onset Segregation Model for Linkage Analysis, with Correction for Ascertainment, Applied to Glioma

223. Supplementary Tables 1-9 from Sleeping Beauty Insertional Mutagenesis Reveals Important Genetic Drivers of Central Nervous System Embryonal Tumors

224. Supplementary Tables 1-5 from Impact of c-MYC Protein Expression on Outcome of Patients with Early-Stage HER2+ Breast Cancer Treated with Adjuvant Trastuzumab NCCTG (Alliance) N9831

225. Supplementary Figure 1 from Association of HER2/ErbB2 Expression and Gene Amplification with Pathologic Features and Prognosis in Esophageal Adenocarcinomas

226. Supplementary Data from Transcriptome-Wide Association Study Identifies New Candidate Susceptibility Genes for Glioma

227. Supplementary Figure 2 from A Variable Age of Onset Segregation Model for Linkage Analysis, with Correction for Ascertainment, Applied to Glioma

228. supp Tables from Development and Validation of a Prostate Cancer Genomic Signature that Predicts Early ADT Treatment Response Following Radical Prostatectomy

229. Supplementary Figures 1-3 from Sleeping Beauty Insertional Mutagenesis Reveals Important Genetic Drivers of Central Nervous System Embryonal Tumors

230. Data from A Heritable Missense Polymorphism in CDKN2A Confers Strong Risk of Childhood Acute Lymphoblastic Leukemia and Is Preferentially Selected during Clonal Evolution

231. Supplementary Data from TOP2A and EZH2 Provide Early Detection of an Aggressive Prostate Cancer Subgroup

232. Supplementary Materials from Genomic and Phenotypic Characterization of a Broad Panel of Patient-Derived Xenografts Reflects the Diversity of Glioblastoma

233. Data from Genomic and Phenotypic Characterization of a Broad Panel of Patient-Derived Xenografts Reflects the Diversity of Glioblastoma

234. Sup Fig 1 from Development and Validation of a Prostate Cancer Genomic Signature that Predicts Early ADT Treatment Response Following Radical Prostatectomy

235. Supplementary Figure 1 from Impact of c-MYC Protein Expression on Outcome of Patients with Early-Stage HER2+ Breast Cancer Treated with Adjuvant Trastuzumab NCCTG (Alliance) N9831

236. Supplementary Tables 1 - 4 from SSBP2 Variants Are Associated with Survival in Glioblastoma Patients

237. Sup Fig 2 from Development and Validation of a Prostate Cancer Genomic Signature that Predicts Early ADT Treatment Response Following Radical Prostatectomy

238. Supplementary Figure 2 from Impact of c-MYC Protein Expression on Outcome of Patients with Early-Stage HER2+ Breast Cancer Treated with Adjuvant Trastuzumab NCCTG (Alliance) N9831

239. Supplementary Figure 3 from Sleeping Beauty–Mediated Somatic Mutagenesis Implicates CSF1 in the Formation of High-Grade Astrocytomas

241. Supplementary Table 5 from Sleeping Beauty–Mediated Somatic Mutagenesis Implicates CSF1 in the Formation of High-Grade Astrocytomas

242. Supplementary Table 3 from Sleeping Beauty–Mediated Somatic Mutagenesis Implicates CSF1 in the Formation of High-Grade Astrocytomas

243. Supplementary Table 1 from Rearrangements and Amplification of IER3 (IEX-1) Represent a Novel and Recurrent Molecular Abnormality in Myelodysplastic Syndromes

244. Data from Rearrangements and Amplification of IER3 (IEX-1) Represent a Novel and Recurrent Molecular Abnormality in Myelodysplastic Syndromes

246. Data from Whole-Body Sleeping Beauty Mutagenesis Can Cause Penetrant Leukemia/Lymphoma and Rare High-Grade Glioma without Associated Embryonic Lethality

247. Supplementary Figure 2 from Sleeping Beauty–Mediated Somatic Mutagenesis Implicates CSF1 in the Formation of High-Grade Astrocytomas

248. Supplementary Figure 1 from Decreased NKX3.1 Protein Expression in Focal Prostatic Atrophy, Prostatic Intraepithelial Neoplasia, and Adenocarcinoma: Association with Gleason Score and Chromosome 8p Deletion

Catalog

Books, media, physical & digital resources